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Purpose: To examine vision-related quality of life in patients with diabetic macular edema (DME) treated with
intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Inc, Tarrytown, NY).
Design: AQUA was a multicenter, open-label, single-arm, phase 4 study.
Participants: Adults 18 years of age or older with type 1 or 2 diabetes mellitus and DME.
Methods: Patients received intravitreal aflibercept 2 mg every 8 weeks for 52 weeks, after 5 initial doses
every 4 weeks.
Main Outcome Measures: The primary outcome was the change in 25-item National Eye Institute Visual
FunctionQuestionnaire (NEI VFQ-25) total score frombaseline toweek 52. Secondary outcomes included the change
in NEI VFQ-25 near and distant activities subscale scores, best-corrected visual acuity (BCVA; Early Treatment
Diabetic Retinopathy Study [ETDRS] letters), and central retinal thickness (CRT) from baseline to week 52. Change in
NEI VFQ-25 score at week 52 for better-seeing eyes (BSEs) and worse-seeing eyes (WSEs) also was evaluated.
Results: A total of 553 patients comprised the full analysis set, and 560 patients comprised the safety
analysis set. At baseline, the mean NEI VFQ-25 total score was 70.12, mean BCVA was 61.5 ETDRS letters, and
mean CRT was 464.81 mm. A mean of 8.8 injections were administered over 52 weeks. At week 52, the mean
improvement from baseline in the NEI VFQ-25 total score was þ6.11 (standard deviation [SD], 11.46); the cor-
responding improvements in near and distant activities were þ11.37 (SD, 18.01) and þ7.33 (SD, 17.32),
respectively. Similarly, improvements in patients whose BSE and WSE were treated were 7.74 (SD, 13.59) and
5.48 (SD, 9.70), respectively. At week 52, mean change in BCVA was þ10.0 ETDRS letters (SD, 8.0 ETDRS
letters), and mean change in CRT was e175.38 mm (SD, 132.62 mm). Overall, 53.6% of patients reported
treatment-emergent adverse events (TEAEs), of whom 26.8% experienced an ocular TEAE in the study eye. The
most common serious ocular TEAE was endophthalmitis (0.5% [n ¼ 3]). Five deaths (0.9%) were reported, but
were not considered treatment related.
Conclusions: Intravitreal aflibercept was associated with clinically meaningful improvements in NEI VFQ-25
total score over 52 weeks in patients with DME; these were even more pronounced for near than for distant
activities. Adverse events were consistent with the known safety profile of intravitreal aflibercept. Ophthalmology
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safety of therapeutic interventions as part of the clinical
decision-making process, patient-reported outcomes are as
important, particularly in the treatment of chronic diseases,
when selecting interventions in a clinical setting.1 Most
randomized clinical trials in retinal disorders focus on
functional and anatomic outcomes for primary and secondary
evaluation, giving limited weight to patient-reported 2019 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.outcomes. However, patient-reported outcomes, including
changes in quality of life (QoL), may play an important role in
patient adherence to treatment.
Diabetic macular edema (DME) is a serious complication
of diabetes mellitus that causes visual impairment in
working-age adults.2,3 The impact of the ocular complica-
tions of diabetes on patient QoL is considerable and ranges
from preliminary symptoms to severe vision loss.4567https://doi.org/10.1016/j.oret.2019.03.012
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patient’s ability to complete daily routine activities, which
can impact the psychological state. Therefore, in addition
to measuring the functional outcome of a therapeutic
intervention, it is also important to measure a treatment’s
impact on vision-related QoL.5 Quality-of-life measure-
ments now are recognized as an integral part of health utility
analyses in many countries,6,7 and the assessment of pa-
tients’ QoL is being implemented into daily clinical thera-
peutic decisions.8 The 25-item National Eye Institute Visual
Function Questionnaire (NEI VFQ-25) is a visual function-
specific QoL assessment tool that has been validated in
patients with DME and other retinal conditions.4,5,7,9 The
NEI VFQ-25 is an established survey to evaluate a patient’s
disease burden and vision-related QoL, and it is sensitive to
the effect of different therapeutic interventions such as
antievascular endothelial growth factor (VEGF) therapy.
The NEI VFQ-25 also allows for assessment of the extent to
which eye disorders impact a patient’s anxiety level and
routine activities, as well as social interactions.7 It has been
used to determine QoL objectively in several phase 3 trials
evaluating the efficacy and safety of intravitreal anti-VEGF
therapy in different retinal indications.10,11 Visual acuity
improvement in patients with DME treated with anti-VEGF
agents has been found to be correlated with enhanced
patient-reported visual function measured with NEI VFQ-
25.12,13
The efficacy and safety of intravitreal aflibercept (EYLEA)
in patients with DME have been established in several phase 3
trials14; however, limited evidence is available on the impact of
intravitreal aflibercept on vision-related QoL, namely the
relative influence of the visual acuity of the better-seeing eye
(BSE) and worse-seeing eye (WSE) on vision-related QoL in
patients with DME. The aim of the AQUA study was to assess
the impact of intravitreal aflibercept treatment onvision-related
QoL outcomes in patients with DME. Herein, we report the
results of the AQUA study.
Methods
Study Design
The AQUA study (http://www.clinicaltrials.gov identifier,
NCT02581995) was a multicenter, open-label, single-arm, phase 4
study to evaluate vision-related QoL in patients with DME who
were treated with intravitreal aflibercept over 52 weeks. Patients
were recruited from 78 study sites across 14 countries in Europe
and Canada. The study was conducted in accordance with the te-
nets of the Declaration of Helsinki and the International Council
for Harmonisation guideline E6: Good Clinical Practice.15e17
Institutional review board or ethics committee approval was ob-
tained: each site had an institutional review board or independent
ethics committee that provided approval for the protocol and the
protocol amendment. Country-specific institutional review boards
or independent ethics committees are listed in Table 1 (available at
www.ophthalmologyretina.org). All patients provided written
informed consent.
Participants
Adults 18 years of age or older with type 1 or 2 diabetes mellitus
and DME with central macular involvement (defined as the area of568the center subfield on OCT) were eligible if best-corrected visual
acuity (BCVA) was between 73 and 24 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters (Snellen equivalent, approxi-
mately 20/40e20/320) in the study eye. The decrease in vision in
the study eye primarily had to be the result of DME. If both eyes
were affected, then 1 eye was chosen by the investigator at base-
line. All exclusion criteria are listed in Table 2 (available at
www.ophthalmologyretina.org).
Treatment
Patients received 5 initial injections at 4-week intervals, followed
by intravitreal aflibercept 2 mg every 8 weeks until week 52.
Treatment was administered in accordance with the European
prescribing information.18 Laser photocoagulation or surgery could
be performed if deemed necessary by the investigator. No other
DME treatment could be administered in the study eye until
study completion or early termination. Any approved
nonsystemic treatment (including intravitreal aflibercept) could
be administered to a fellow eye with DME, but only 1 eye per
patient was included in the study.
Assessments
The NEI VFQ-25 was administered at screening (up to 4 weeks
before baseline); at baseline (day 1, pretreatment); at weeks 4, 8, 12,
and 16 (5 days); at weeks 24 through 48 (10 days); and at week
52 (10 days). The NEI VFQ-25 questionnaire was presented in the
local language and administered in a quiet room by a study-related
person qualified to administer this type of questionnaire, prefer-
ably before other visit procedures were performed. Patients unable to
read the questionnaire because of vision impairment could be
assisted by a family member other legal representative of the patient,
study nurse, or study physician in completing the questionnaire. A
summary of the NEI VFQ-25 questionnaire is provided in Table 3
(available at www.ophthalmologyretina.org). Visual acuity was
assessed using the ETDRS protocol. Macular and DME
characteristics were evaluated using spectral-domain OCT. Addi-
tionally, the anatomic state of the retinal vasculature (study eye) was
evaluated by funduscopic examination, fundus photography, and
fluorescein angiography.
Safety was monitored throughout the study, and all adverse
events were classified according to the Medical Dictionary for
Regulatory Activities (version 20). All information on intensity,
causal relationship to intravitreal aflibercept, action taken or
treatment, and outcome was recorded in the electronic case report
form. Treatment-emergent adverse events (TEAEs) were defined as
those that started after the first intravitreal aflibercept injection, but
not more than 30 days after the last injection. Potential arterial
thrombotic events were evaluated by an Antiplatelet Trialists’
Collaboration adjudication committee in accordance with pub-
lished criteria.19
Statistical Analyses
The primary outcome was the change in the NEI VFQ-25 total score
from baseline to week 52. Secondary outcomes included the NEI
VFQ-25 subscale scores for near and distant activities, mean change
in BCVA (ETDRS letters), mean change in central retinal thickness
(CRT) on OCT (from baseline to week 52), and the proportion of
patients progressing to proliferative diabetic retinopathy (PDR) as
measured by a score of at least 61 on the ETDRS Diabetic Reti-
nopathy Severity Scale (DRSS). The DRSS was assessed on fundus
photography by the central reading center at week 52. In addition,
further outcomes were prespecified, including the proportion of eyes
gaining or losing 0 or more ETDRS letters, 5 or more ETDRS letters,
10 or more ETDRS letters, and 15 or more ETDRS letters at week 52
Table 4. Baseline Characteristics
Characteristic Data
Patient characteristics n ¼ 560
Age (yrs), mean (SD) 64.3 (9.3)
Male gender 336 (60.0)





American Indian or Alaska Native 0
Native Hawaiian or other Pacific Islander 0
Not reported 34 (6.1)
Ethnicity
Hispanic or Latino 1 (0.2)
Not Hispanic or Latino 526 (93.9)
Not reported 33 (5.9)
Study eye
Better-seeing eye 116 (20.7)
Worse-seeing eye 337 (60.2)
Equal vision 104 (18.6)
Missing 3 (0.5)
Patients with prior use
of anti-VEGF agents*
140 (25.3)
Patients who had not used
anti-VEGF therapy before this study*
413 (74.7)
Baseline disease characteristics n ¼ 560
Diabetes mellitus type 2 515 (92.0)
NEI VFQ-25 total score, mean (SD) 70.12 (19.24)
BCVA (ETDRS letters), mean (SD) 61.5 (10.9)
CRT (mm), mean (SD) 464.81 (136.21)
DRSS score (study eye)
10, DR absent 0
15, DR questionable 2 (0.4)
35, mild NPDR 148 (26.4)
43, moderate NPDR 185 (33.0)
47, moderately severe NPDR 153 (27.3)
53, severe NPDR 48 (8.6)
61, mild PDR 8 (1.4)
65, moderate PDR 8 (1.4)
71, high-risk PDR 2 (0.4)
90, cannot grade 6 (1.1)
BCVA ¼ best-corrected visual acuity; BMI ¼ body mass index; CRT ¼
central retinal thickness; DR ¼ diabetic retinopathy; DRSS ¼ Diabetic
Retinopathy Severity Scale; ETDRS ¼ Early Treatment Diabetic Reti-
nopathy Study; NEI VFQ-25 ¼ 25-item National Eye Institute Visual
Function Questionnaire; NPDR ¼ nonproliferative diabetic retinopathy;
PDR ¼ proliferative diabetic retinopathy; SD ¼ standard deviation;
VEGF ¼ vascular endothelial growth factor.
Values are no. (%) unless otherwise indicated.
*Full analysis set, n ¼ 553.
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improvement in DRSS score (defined as patients whose DRSS
category decreased by 2 or 3 levels, respectively) at week 52.
The primary and secondary efficacy outcomes were analyzed
descriptively. For continuous outcomes, 95% confidence intervals
(CIs) were provided based on the t distribution assuming that the
changes from baseline are distributed normally. Missing values
were imputed using the last observation carried forward approach.
The calculations for NEI VFQ-25 total and subscale scores
were performed in accordance with the NEI VFQ-25 scoring
algorithm (version August 2000). Previous publications also have
reported that the minimal clinically important difference (MCID)for the change in the NEI VFQ-25 scores is 4 to 6.20 Based on this,
an MCID of 5 or more for change from baseline to week 52 in NEI
VFQ-25 scores was used for the summaries.
Because either the BSE or the WSE could be chosen as the
study eye, exploratory analyses were performed to evaluate the
relative influence of the visual acuity of BSEs and WSEs on the
NEI VFQ-25 total score. Impact of prior use of anti-VEGF agents
on NEI VFQ-25 total score also was assessed.
All efficacy parameters were evaluated using the full analysis
set (FAS), defined as all patients who received at least 1 intravitreal
aflibercept injection and who completed baseline and at least 1
postbaseline NEI VFQ-25 assessment. The safety analysis set
included all patients who received at least 1 intravitreal aflibercept
injection.
Assuming a similar variability (standard deviation [SD], 11) as
in previous studies, with the enrolled sample size of 553 patients in
the full analysis set, the difference between the mean and the limits
of the 95% CIs was expected not to exceed 1.0 with a probability
of 90% or more. All statistical analyses were performed using SAS
for Windows, version 9.3 (SAS Institute, Inc, Cary, NC).
Results
Study Population
A total of 560 patients were included in the safety analysis set and
553 patients were included in the full analysis set; 529 patients
completed the study. Most premature discontinuations primarily
were the result ofwithdrawal by patients (n¼ 12 [2.1%]) and adverse
events (n ¼ 6 [1.1%]); the remainder were the result of being lost to
follow-up (n¼ 5 [0.9%]), death (n¼ 4 [0.7%]; 1 death occurred after
the patient completed the study), sponsor decision (n¼ 1 [0.2%]), or
other reasons (n ¼ 3 [0.5%]).
The overall mean age was 64.3 years, and more than half of the
patients (n ¼ 336 [60.0%]) were men. Most patients were white
(n ¼ 519 [92.7%]) and non-Hispanic or Latino (n ¼ 526 [93.9%];
Table 4). Most patients had type 2 diabetes mellitus at baseline
(n ¼ 515 [92.0%]) with a mean duration of 16.4 years. At baseline,
more WSEs were treated (n ¼ 337 [60.2%]) than BSEs (n ¼ 116
[20.7%]); 18.6% of patients (n ¼ 104) showed equal vision in both
the study eye and the fellow untreated eye. Most patients had not
used anti-VEGF agents before this study (n ¼ 413 [74.7%]). At
baseline, the mean NEI VFQ-25 total score was 70.12 (SD, 19.24),
mean BCVA was 61.5 ETDRS letters (SD, 10.9 ETDRS letters;
Snellen equivalent, 20/59), and mean CRT was 464.81 mm (SD,
136.21 mm). The most common DRSS score in the study eye was 43
(moderate nonproliferative diabetic retinopathy [NPDR]), occurring
in approximately 33%of patients (n¼ 185; Table 4). Overall, 1.4% of
patients (n ¼ 8) showed a DRSS score of 61 (mild PDR) and 65
(moderate PDR) each and 0.4% of patients (n ¼ 2) showed a DRSS
score of 71 (high-risk PDR; Table 4).
Treatment Exposure
The mean number of injections over 52 weeks was 8.8 (95% CI,
8.7e8.9). Most patients (n ¼ 508 [91.9%]) received all 9 injections
per the trial’s treatment regimen.
Efficacy Outcomes
Quality of Life Outcomes. The mean NEI VFQ-25 total score
improved from 70.12 (SD, 19.24) at baseline to 76.33 (SD, 18.76) at569
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Fig 1; Table 5). A total of 75.2% of patients (n¼ 416) experienced an
improvement and 23.3% (n¼ 129) showed a decline in NEIVFQ-25
total score at week 52. The percentage of patients with no change in
NEI VFQ-25 total score was 1.4% (n ¼ 8) at week 52 (Table 5).
Approximately half of patients (50.3% [n ¼ 278]) were able to
achieve or exceed the MCID over 52 weeks.
Patients whose BSE was treated (n ¼ 112) showed a mean
improvement in NEI VFQ-25 score of 7.74 (SD, 13.59; 95% CI,
5.6e9.9), and those whose WSE was treated (n ¼ 334) showed an
improvement of 5.48 (SD, 9.70; 95% CI, 4.6e6.4) at week 52 (Fig 2;
Table 5). Patients with equal vision in the study eye and the fellow
untreated eye (n ¼ 104) showed a mean improvement in NEI VFQ-
25 total score of 6.47 (SD, 13.13; 95% CI, 4.3e8.6) at week 52.
Mean NEI VFQ-25 subscale score for near activities improved
from 62.97 (SD, 23.48) at baseline to 74.34 (SD, 23.44) at week
52; the mean change was 11.37 (SD, 18.01; 95% CI, 10.1e12.6).
For distant activities, the mean NEI VFQ-25 subscale score
improved from 71.96 (SD, 23.97) at baseline to 79.30 (SD, 23.44)
at week 52; the mean change was 7.33 (SD, 17.32; 95% CI,
6.1e8.5; Fig 1; Table 5). At week 52, 63.8% of patients showed
improvement in the near activities subscale. Similarly, the
percentage of patients who achieved or exceeded MCID for the
near activities subscale at week 52 was 63.8%. For distant
activities, 50.1% of patients showed improvement at week 52
and 49.5% of patients achieved or exceeded MCID at week 52.
At week 52, the subgroup of patients who had received prior
anti-VEGF therapy showed a mean improvement of 5.08 (SD,
10.99; 95% CI, 3.5e6.6) from baseline (mean, 71.40; SD, 18.22)
in NEI VFQ-25 total score. Patients who had not received prior
anti-VEGF therapy showed a mean improvement of 6.45 (SD,
11.61; 95% CI, 5.5e7.4) in NEI VFQ-25 total score from baseline
(mean, 69.82; SD, 19.56) to week 52.
Visual and Anatomic Outcomes
The mean BCVA increased to 71.5 ETDRS letters (SD, 11.5 ETDRS
letters; Snellen equivalent, 20/37) at week 52, representing amean gainFigure 1. Graph showing mean change in 25-item National Eye Institute V
observation carried forward).
570of 10.0 ETDRS letters (SD, 8.0 ETDRS letters; 95% CI, 9.5e10.6
ETDRS letters) from baseline to week 52 (Fig 3; Table 6). The
proportion of patients gaining 15 ETDRS letters or more, 10 ETDRS
letters or more, and 5 ETDRS letters or more over 52 weeks was
26.2% (n ¼ 145), 51.9% (n ¼ 287), and 75.2% (n ¼ 416),
respectively (Table 6). In comparison, the proportion of patients
losing 15 ETDRS letters or more, 10 ETDRS letters or more, and 5
ETDRS letters or more over 52 weeks was 0.4% (n ¼ 2), 0.7%
(n ¼ 4), and 2.2% (n ¼ 12), respectively (Table 6). Regression
analysis illustrated the positive correlation between change in NEI
VFQ-25 total score and difference in maximum BCVA in the BSE
(r ¼ 0.2005; Fig 4). At week 52, mean CRT was 289.15 mm (SD,
76.15 mm), and the mean change in CRT from baseline to week 52
was e175.38 mm (SD, 132.62 mm; 95% CI, 184.9e165.8 mm;
Table 6).Diabetic Retinopathy Severity Score Outcomes
At week 52, 2.0% of patients (n ¼ 10) showed PDR. A total of
20.5% and 3.4% of study eyes showed a 2-step or more and 3-
step or more DRSS score improvement from baseline to week
52, respectively, as assessed by the central reading center
(Table 6).Safety Outcomes
In total, 53.6% patients (n ¼ 300) experienced a TEAE, of whom
26.8% (n ¼ 150) experienced an ocular TEAE in the study eye,
32.3% (n ¼ 181) experienced a nonocular TEAE, and 1.8% (n ¼
10) experienced a treatment-emergent Antiplatelet Trialists’
Collaboration event (Table 7). Endophthalmitis was reported as
being treatment emergent in 3 of 560 patients (0.5%) after the
application of 4889 intravitreal aflibercept injections (0.06% of
injections). Five deaths (0.9%; including 1 death that occurred
after the patient completed the study) were reported during the
treatment period, but none were considered to be related to
treatment (Table 7).isual Function Questionnaire (NEI VFQ-25) score (full analysis set, last
Table 5. Quality of Life Efficacy Outcomes at Week 52
Quality of Life Outcomes, 25-Item National
Eye Institute Visual Function




Change in total score, mean (SD)
All patients 6.11 (11.46)
BSE as study eye 7.74 (13.59)
WSE as study eye 5.48 (9.70)
Equal vision in study eye and
fellow untreated eye
6.47 (13.13)
Improvement in total score, no. (%) 416 (75.2)
Worsening in total score, no. (%) 129 (23.3)
No change in total score, no. (%) 8 (1.4)
Change in near activities subscale
score, mean (SD)
11.37 (18.01)
Change in distant activities subscale
score, mean (SD)
7.33 (17.32)
BSE ¼ better-seeing eye; SD ¼ standard deviation; WSE ¼ worse-seeing
eye.
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The AQUA trial demonstrated that the treatment of DME
with intravitreal aflibercept results in steady and substantial
improvements in vision-related QoL as measured by NEI
VFQ-25 total score over 52 weeks. The course of the
improvement in NEI VFQ-25 closely resembled improve-
ment in BCVA over time. A consistent increase in the mean
NEI VFQ-25 total scores was observed in patients whose
BSE was treated and in those whose WSE was treated
throughout the study, but was more pronounced in the
former. This difference can be attributed to the fact that for
vision-related QoL, patient-reported outcome measures such
as NEI VFQ-25 score is assessed for both eyes; however,
the outcome usually is driven by the visual acuity in theFigure 2. Graph showing mean change in 25-item National Eye Institute Visua
(BSE) and worse-seeing eye (WSE; full analysis set, last observation carried forBSE.20 Nearly similar improvements (but slightly less than
in patients whose BSE was treated) in NEI VFQ-25 total
score were observed over 52 weeks in the subgroup of
patients with equal vision in the study eye and fellow
untreated eye. A slightly greater improvement in the NEI
VFQ-25 subscale score for near activities than for distant
activities was observed, which could be the result of a
higher baseline mean NEI VFQ-25 score for distant
activities than for near activities. There also may be a
stronger relationship between functional outcomes and
near vision compared with distance vision. More
than 75% of patients experienced an improvement in
NEI VFQ-25 total score at week 52. Although not
specifically analyzed, it is possible that numerically lower
NEI VFQ-25 total scores compared with baseline at week
52 in a subset of patients could be the result of high
BCVA at screening or of comorbidities. At week 52, only
6.7% of patients lost 0 letters or more and only 2.2% of
patients demonstrated a 5-letter or more loss. Prior use of
anti-VEGF agents did not seem to influence the increase in
NEI VFQ-25 total score greatly, because patients who had
not used anti-VEGF agents before showed a slightly lower
mean NEI VFQ-25 score at baseline than did those who
previously had received anti-VEGF agents (69.82 [SD,
19.56] vs. 71.40 [SD, 18.22], respectively) and showed a
slightly larger mean improvement (6.45 vs. 5.08) over the
52-week treatment period. A steady improvement in BCVA
also was observed over the 52-week study duration. At
week 52, approximately one quarter of the patients gained
15 letters or more in BCVA scores.
These results are in line with the results from the
Intravitreal Aflibercept Injection in Vision Impairment due
to DME (VIVID-DME) study and the Study of Intravitreal
Aflibercept Injection in Patients with Diabetic Macular
Edema (VISTA-DME); for near activities, the AQUA
study results were more aligned with the VISTA-DME
study in which the mean change in NEI VFQ-25 over 52l Function Questionnaire (NEI VFQ-25) total score in the better-seeing eye
ward).
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Figure 3. Graph showing mean change in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters; full analysis
set, last observation carried forward; n ¼ 553).




Aflibercept (n [ 553)
Change in BCVA (ETDRS letters),
mean (SD)
þ10 (8.0)
Change in CRT (mm), no. (%) e175.38 (132.62)
15-letter gain 145 (26.2)
10-letter gain 287 (51.9)
5-letter gain 416 (75.2)
0-letter gain 516 (93.3)
0-letter loss 37 (6.7)
5-letter loss 12 (2.2)
10-letter loss 4 (0.7)
15-letter loss 2 (0.4)
2-step DRSS score improvement,
no./total no. (%)
103/502 (20.5)
3-step DRSS score improvement,
no./total no. (%)
17/502 (3.4)
BCVA ¼ best-corrected visual acuity; CRT ¼ central retinal thickness;
DRSS ¼ Diabetic Retinopathy Severity Scale; ETDRS ¼ Early Treatment
Diabetic Retinopathy Study; SD ¼ standard deviation.
All data are number of patients (%) unless otherwise indicated.
Ophthalmology Retina Volume 3, Number 7, July 2019weeks was 9.4 in the intravitreal aflibercept 2 mg every 8
weeks treatment group. The corresponding mean change in
the intravitreal aflibercept 2 mg every 8 weeks arm of
VIVID-DME study was 5.3. Similarly, the mean change in
NEI VFQ-25 score over 52 weeks for distant activities was
5.3 and 7.3 in the intravitreal aflibercept 2 mg every 8 weeks
treatment group of the VIVID-DME and VISTA-DME
studies, respectively.13,21 Our findings are consistent with
those of previous large clinical studies that reported im-
provements in vision-related QoL in patients treated with
other anti-VEGF agents22,23 and other available treatments23
for DME and have established further the effectiveness of
anti-VEGF therapy in improving vision-related QoL to a
clinically meaningful extent over 52 weeks in patients with
DME.
In addition to the vision-related QoL outcomes, func-
tional outcomes of the AQUA study also were consistent
with the results from VIVID-DME and VISTA-DME, in
which mean change in BCVA over 52 weeks was þ10.7
letters in the intravitreal aflibercept 2 mg every 8 weeks
treatment group of both the studies.13,21 These similarities
among the AQUA study and VIVID-DME and VISTA-
DME studies in BCVA also were accompanied by
improvement in anatomic outcomes; mean change in CRT
from baseline for the intravitreal aflibercept 2 mg every 8
weeks group was e192.4 mm and 183.1 mm in the VIVID-
DME and VISTA-DME studies, respectively.13,21 Compa-
rable with the AQUA study, the proportions of patients
gaining 15 letters or more were 33.3% and 31.3% in the
intravitreal aflibercept 2 mg every 8 weeks groups of the
VIVID-DME and VISTA-DME studies, respectively.13,21
The corresponding percentages of eyes that gained 10 let-
ters or more were 53.3% and 58.3% in the VIVID-DME and
VISTA-DME studies, respectively. However, DRSS out-
comes in the AQUA study differed slightly from those of
the VIVID-DME and VISTA-DME studies; at week 52,
27.7% and 29.1% patients were 2-step or more improvers in572the intravitreal aflibercept 2 mg every 8 weeks groups of the
VIVID-DME and VISTA-DME studies, respectively. This
variation in DRSS outcomes could be the result of differ-
ences in the distribution of baseline DRSS scores between
the AQUA study and the EYLEA phase 3 trials, because
baseline DR severity is a major predictor of improvement
with anti-VEGF therapies. The proportion of patients with
severe NPDR (DRSS score of 53) at baseline was greater in
the intravitreal aflibercept 2 mg every 8 weeks group of the
VIVID-DME and VISTA-DME studies than in the AQUA
study (31.1% and 26.5% vs. 8.6%), whereas the proportion
of patients with mild NPDR (DRSS score of 35) was lower
(0.7% and 6.0% vs. 26.4%).13,21
Figure 4. Scatterplot showing correlation between mean change in 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) score and
difference in maximum best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters; LOESS ¼ locally estimated
scatterplot smoothing; full analysis set, last observation carried forward).
Table 7. Safety Outcomes Over 52 Weeks
Intravitreal
Aflibercept (n [ 560)
Any TEAE 300 (53.6)
Any treatment-emergent SAEs 66 (11.8)
Any ocular TEAE (study eye) 150 (26.8)
Treatment-emergent ocular SAEs in study eye
Patients with at least 1 treatment-emergent
ocular SAE
6 (1.1)
Eye disorders 3 (0.5)
Vitreitis 2 (0.4)
Anterior chamber inflammation 1 (0.2)
Cataract subcapsular 1 (0.2)
Posterior capsule opacification 1 (0.2)
Infections and infestations 3 (0.5)
Endophthalmitis 3 (0.5)
Any nonocular TEAE 181 (32.3)
Any treatment-emergent APTC event 10 (1.8)
Patients with SAEs with fatal outcomes, death 5 (0.9)
Cardiopulmonary failure* 1 (0.2)
Pneumonia* 1 (0.2)
Cardiorespiratory arrest 1 (0.2)
Cardiovascular insufficiency 1 (0.2)
Vascular encephalopathy 1 (0.2)
Myocardial infarction 1 (0.2)
APTC ¼ Anti-Platelet Trialists’ Collaboration; SAE ¼ serious adverse
event; TEAE ¼ treatment-emergent adverse event.
All data are number of patients (%). All events were considered not related
to study drug by the investigator.
*One patient experienced 2 events with a fatal outcome.
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study, and intravitreal aflibercept was well tolerated over 52
weeks. The safety profile of intravitreal aflibercept for the
treatment of DME in this study was consistent with that in
other studies of intravitreal aflibercept.13,21
The NEI VFQ-25 assesses the impact of visual disability
on patients’ overall health domains, such as emotional well
being, social functioning, and daily visual function.7
Evidence from the literature suggests a strong association
between visual functioning and vision-related QoL derived
from ophthalmologic-specific measures, such as the NEI
VFQ-25, in various retinal complications.9 Previous research
has found a correlation between decreased visual function and
development of depression, which in turn affects patients’
daily activities. Higher incidence of depressive disorders in
patients with advanced age-related macular degeneration
and other retinal diseases, comparable with rates seen in pa-
tients with life-threatening diseases such as cancer or cere-
brovascular diseases, supports these observations.24,25 Thus,
improving NEI VFQ-25 scores can help clinicians to provide
patients with optimized medical treatment, further increasing
treatment adherence and persistence.7
The large patient population included in this study, the use
of NEI VFQ-25 assessment score, and the prospective design
are strengths of the AQUA study. However, this study did not
stratify patients according to their baseline visual acuity, and
there may be relevant differences in score changes in patients
with a BCVA of fewer than 70 letters (Snellen equivalent,
20/40) compared with those with a BCVA of 70 letters or573
Ophthalmology Retina Volume 3, Number 7, July 2019more. Similarly, patients were not stratified by baseline DRSS
score, and there may be differences in NEI VFQ-25 score
changes in patients with mild NPDR compared with those
who have severe NPDR at baseline.26 There was a difference
observed in NEI VFQ-25 total score for patients who received
prior anti-VEGF agents compared with those who did not,
with anti-VEGF treatment-naïve patients achieving a slightly
higher score. This study did not assess the correlation be-
tween letter gain categories and change in QoL scores;
however, a positive correlationwas observed between change
in NEI VFQ-25 score and difference in maximum BCVA in
the BSE. Moreover, the potential impact of comorbidities of
diabetes on the NEI VFQ-25 scores has not been included.
In conclusion, use of intravitreal aflibercept was associ-
ated with clinically meaningful and patient-relevant im-
provements in NEI VFQ-25 total score, as well as subscale
scores for near and distant vision, along with visual and
functional outcomes over 52 weeks in this phase 4 study of
patients with DME.References
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erico Ricci, Bozena Romanowska-Dixon, Helmut G. Sachs, Saddek
Mohand-Said, Dirk Sandner, Ursula Schmidt-Erfurth, Walter Sekundo,
Andras Seres, Sobha Sivaprasad, Eric Souied, João Castro de Sousa,
Andrzej Stankiewicz, Jana Stefanicková, Katarína Struhárová, JanStudnicka, Enrique Cervera Taulet, Simon Taylor, Slawomir Teper, Attila
Vajas, Carlos Cava Valenciano, Balázs Varsányi, Francesco Viola, Gianni
Virgili, Lars Wagenfeld, Gavin Walters, Peter Wiedemann, Tomasz
Zarnowski.
Supported by Bayer AG, Berlin, Germany. The sponsor or funding orga-
nization participated in the design of the study; conducting the study; data
analysis; interpretation of the data; and preparation, review, and approval of
the manuscript.
Medical writing assistance was provided by Deepti Sharda and Melanie
Meister-Broekema of PAREXEL, and was funded by Bayer.
HUMAN SUBJECTS: Human subjects were included in this study. The
study was conducted in 78 sites across 14 countries in Europe and Canada.
Institutional review board or ethics committee approval was obtained at
each site before, and informed consent to participate in the study was ob-
tained from all patients. All information presented in this study complies
with the Health Insurance Portability and Accountability Act for United
States sites. The study was performed in accordance with the tenets of the
Declaration of Helsinki.
No animal subjects were included in this study.
Author Contributions:
Conception and design: Garweg, Stefanickova, Hoyng, Schmelter, Niesen,
Sowade, Sivaprasad
Analysis and interpretation: Garweg, Stefanickova, Hoyng, Schmelter,
Niesen, Sowade, Sivaprasad
Data collection: Garweg, Stefanickova, Hoyng, Sivaprasad
Obtained funding: N/A
Overall responsibility: Garweg, Stefanickova, Hoyng, Schmelter, Niesen,
Sowade, Sivaprasad
Abbreviations and Acronyms:
ATE ¼ arterial thrombotic event; BCVA ¼ best-corrected visual acuity;
BSE ¼ better-seeing eye; CI ¼ confidence interval; CRT ¼ central retinal
thickness; DME ¼ diabetic macular edema; DRSS ¼ Diabetic Retinopathy
Severity Scale; ETDRS ¼ Early Treatment Diabetic Retinopathy Study;
FAS ¼ full analysis set; MCID ¼ minimal clinically important difference;
NEI VFQ-25 ¼ 25-item National Eye Institute Visual Function Ques-
tionnaire; NPDR ¼ nonproliferative diabetic retinopathy;
PDR ¼ proliferative diabetic retinopathy; QoL ¼ quality of life;
SD ¼ standard deviation; TEAE ¼ treatment-emergent adverse event;
VEGF ¼ vascular endothelial growth factor; VISTA ¼ Study of Intra-
vitreal Aflibercept Injection in Patients with Diabetic Macular Edema;
VIVID ¼ Intravitreal Aflibercept Injection in Vision Impairment due to
DME; WSE ¼ worse-seeing eye.
Correspondence:
Justus G. Garweg, MD, PhD, Berner Augenklinik am Lindenhofspital,
Bremgartenstrasse 119(Y), CH-3012 Bern, Switzerland, and Swiss Eye
Institute, Luzerner Strasse 1, CH-6343 Rotkreuz, Switzerland. E-mail:
justus.garweg@augenklinik-bern.ch.575
